化疗诱导胶质母细胞瘤衰老的机制与清除策略

doi:10.3969/j.issn.1004-616x.2025.04.008

摘要/Abstract

摘要： 胶质母细胞瘤(GBM)是成人中最常见且高度恶性的原发性脑肿瘤，尽管对传统治疗反应良好，但易复发且复发后更具侵袭性和耐药性。化疗作为GBM的重要治疗手段之一，其诱导的细胞衰老可能为肿瘤提供生存优势，从而在一定程度上促进肿瘤耐药的形成和复发。本综述首先评估了影响GBM化疗耐药的关键因素，包括基因突变、缺氧、胶质瘤干细胞、代谢改变以及肿瘤微环境等。随后回顾了细胞衰老的特征及其生物标志物，并探讨了化疗诱导GBM衰老的机制。最后，总结了针对化疗诱导衰老的治疗策略，包括靶向衰老相关分泌表型(SASP)、清除衰老细胞以及联合治疗等。这些策略旨在优化GBM的治疗效果，减少肿瘤复发，提高患者生存率。未来研究应进一步探索衰老细胞的逃逸机制和SASP的双重作用，为GBM治疗提供新的思路和方法。

关键词: 化疗耐药, 胶质母细胞瘤, 衰老, 肿瘤治疗, 肿瘤复发

中图分类号:

R739.41

李怀旭, 肖汀. 化疗诱导胶质母细胞瘤衰老的机制与清除策略[J]. 癌变·畸变·突变, 2025, 37(4): 288-291.

LI Huaixu, XIAO Ting. Mechanisms and elimination strategies of chemotherapy-induced senescence in glioblastoma[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2025, 37(4): 288-291.

参考文献

[1] SAHOO L, PAIKRAY S K, TRIPATHY N S, et al. Advancements in nanotheranostics for glioma therapy[J]. Naunyn Schmiedeberg’s Arch Pharmacol, 2025, 398(3): 2587-2608.
[2] LEONE A, COLAMARIA A, FOCHI N P, et al. Recurrent glioblastoma treatment: state of the art and future perspectives in the precision medicine era[J]. Biomedicines, 2022, 10(8): 1927.
[3] ERICES J I, BIZAMA C, NIECHI I, et al. Glioblastoma microenvironment and invasiveness: new insights and therapeutic targets[J]. Int J Mol Sci, 2023, 24(8): 7047.
[4] SALLBACH J, WOODS M, RASENBERGER B, et al. The cell cycle inhibitor p21^CIP1 is essential for irinotecan-induced senescence and plays a decisive role in re-sensitization of temozolomide-resistant glioblastoma cells to irinotecan[J]. Biomed Pharmacother, 2024, 181: 117634.
[5] BELTZIG L, CHRISTMANN M, KAINA B. Abrogation of cellular senescence induced by temozolomide in glioblastoma cells: search for senolytics[J]. Cells, 2022, 11(16): 2588.
[6] KAINA B. Temozolomide, procarbazine and nitrosoureas in the therapy of malignant gliomas: update of mechanisms, drug resistance and therapeutic implications[J]. J Clin Med, 2023, 12(23): 7442.
[7] REZAEI T, HEJAZI M, MANSOORI B, et al. microRNA-181a mediates the chemo-sensitivity of glioblastoma to carmustine and regulates cell proliferation, migration, and apoptosis[J]. Eur J Pharmacol, 2020, 888: 173483.
[8] ZUCHEGNA C, LEONE S, ROMANO A, et al. KRAS is a molecular determinant of platinum responsiveness in glioblastoma[J]. BMC Cancer, 2024, 24(1): 77.
[9] PHAM J, COTE D J, KANG K, et al. Treatment practices and survival outcomes for IDH-wildtype glioblastoma patients according to MGMT promoter methylation status: insights from the U.S. National Cancer Database[J]. J Neurooncol, 2025, 172(3): 655-665.
[10] HO K H, HSU S Y, CHEN P H, et al. Hypoxia enhances IL-8 signaling through inhibiting miR-128-3p expression in glioblastomas[J]. Biochim Biophys Acta BBA Mol Cell Res, 2025, 1872(2): 119885.
[11] TAO W W, CHU C W, ZHOU W C, et al. Dual Role of WISP1 in maintaining glioma stem cells and tumor-supportive macrophages in glioblastoma[J]. Nat Commun, 2020, 11(1): 3015.
[12] MALHOTRA D, GABRANI R. Metabolic shifts in glioblastoma: unraveling altered pathways and exploring novel therapeutic avenues[J]. Mol Biol Rep, 2025, 52(1): 146.
[13] YU T, WANG K, WANG J W, et al. M-MDSCs mediated trans-BBB drug delivery for suppression of glioblastoma recurrence post-standard treatment[J]. J Control Release, 2024, 369: 199-214.
[14] HAYFLICK L, MOORHEAD P S. The serial cultivation of human diploid cell strains[J]. Exp Cell Res, 1961, 25: 585-621.
[15] PARK J W, BAE Y S. Downregulation of JMJD2a and LSD1 is involved in CK2 inhibition-mediated cellular senescence through the p53-SUV39h1 pathway[J]. BMB Rep, 2022, 55(2): 92-97.
[16] DHOKIA V, MOSS J A Y, MACIP S, et al. At the crossroads of life and death: the proteins that influence cell fate decisions[J]. Cancers (Basel), 2022, 14(11): 2745.
[17] PRINCILLY J, VEERABHADRAPPA B, RAO N N, et al. Cellular senescence in aging: Molecular basis, implications and therapeutic interventions[J]. Adv Protein Chem Struct Biol, 2023, 136: 1-33.
[18] CUI H, FU L Q, TENG Y, et al. Human hair follicle mesenchymal stem cell-derived exosomes attenuate UVB-induced photoaging via the miR-125b-5p/TGF-β1/smad axis[J]. Biomater Res, 2025, 29: 0121.
[19] BARRIUSO D, ALVAREZ-FRUTOS L, GONZALEZ-GUTIERREZ L, et al. Involvement of bcl-2 family proteins in tetraploidization-related senescence[J]. Int J Mol Sci, 2023, 24(7): 6374.
[20] ZHOU Y C, ZENG L, CAI L B, et al. Cellular senescence-associated gene IFI16 promotes HMOX1-dependent evasion of ferroptosis and radioresistance in glioblastoma[J]. Nat Commun, 2025, 16(1): 1212.
[21] LI C H, YUAN Y X, JIA Y D, et al. Cellular senescence: from homeostasis to pathological implications and therapeutic strategies[J]. Front Immunol, 2025, 16: 1534263.
[22] ALHADDAD L, NOFAL Z, PUSTOVALOVA M, et al. Long-term cultured human glioblastoma multiforme cells demonstrate increased radiosensitivity and senescence-associated secretory phenotype in response to irradiation[J]. Int J Mol Sci, 2023, 24(3): 2002.
[23] PUTAVET D A, DE KEIZER P L J. Residual disease in glioma recurrence: a dangerous liaison with senescence[J]. Cancers (Basel), 2021, 13(7): 1560.
[24] AASLAND D, G-TZINGER L, HAUCK L, et al. Temozolomide induces senescence and repression of DNA repair pathways in glioblastoma cells via activation of ATR-CHK1, p21, and NF-κB[J]. Cancer Res, 2019, 79(1): 99-113.
[25] TANAKA Y, NAKAZAWA T, NAKAMURA M, et al. Ex vivo-expanded highly purified natural killer cells in combination with temozolomide induce antitumor effects in human glioblastoma cells in vitro[J]. PLoS One, 2019, 14(3): e0212455.
[26] KUMAR R, GONT A, PERKINS T J, et al. Induction of senescence in primary glioblastoma cells by serum and TGFβ[J]. Sci Rep, 2017, 7(1): 2156.
[27] TOMIMATSU N, DI CRISTOFARO L F M, KANJI S, et al. Targeting cIAP2 in a novel senolytic strategy prevents glioblastoma recurrence after radiotherapy[J]. EMBO Mol Med, 2025, 17(4): 645-678.
[28] CHOJAK R, FARES J, PETROSYAN E, et al. Cellular senescence in glioma[J]. J Neurooncol, 2023, 164(1): 11-29.
[29] FLETCHER-SANANIKONE E, KANJI S M, TOMIMATSU N, et al. Elimination of radiation-induced senescence in the brain tumor microenvironment attenuates glioblastoma recurrence[J]. Cancer Res, 2021, 81(23): 5935-5947.
[30] WEE C W, LEE J H, LEE H I, et al. To use or not to use: temozolomide in elderly patients with IDH wild-type MGMT promoter unmethylated glioblastoma treated with radiotherapy[J]. Cancer Res Treat, 2024.
[31] PUCA A A, LOPARDO V, MONTELLA F, et al. The longevity-associated variant of BPIFB4 reduces senescence in glioma cells and in patients—lymphocytes favoring chemotherapy efficacy[J]. Cells, 2022, 11(2): 294.